A sthma exacerbations are the leading sources of hospital admissions for children in the United States. [1] [2] [3] [4] Children younger than 5 years have the highest rate of hospital admissions because of asthma, and this population continues to show the greatest increases in morbidity. Between 1980 and 1995, reported asthma increased by Ͼ160% in very young children (infants through 4 years of age) compared with the significant but substantially smaller increase of approximately 74% in school-age children (between 5 and 14 years of age). During the same period, hospitalizations for asthma rose by approximately 45% for very young children compared with just Ͼ13% for school-age children. 2 Children who live in impoverished urban areas are especially at risk, with significant rates of unscheduled urgent care visits and hospitalizations for sudden, severe asthma. 5 These increases in asthma and associated morbidity have occurred despite recent advances in treatment and the availability of various national and international guidelines for managing asthma. 4,6 -14 Although there are several possible explanations for increased disease prevalence (eg, better diagnostic criteria, earlier diagnosis, changing environmental factors), the fact remains that there exists significant variation in medical care for children who experience an asthma exacerbation. 5 This is particularly true for the youngest patients. Outpatient emergency care for children with asthma has improved since the first publication of national guidelines in 1992. 15, 16 The 2 most obvious trends have been increased use of pulmonary function testing in capable children and the early administration of systemic corticosteroids for pediatric acute asthma seen in the emergency department (ED). 3, [15] [16] [17] [18] [19] Nonetheless, there remains considerable heterogeneity in the treatment of acute asthma, particularly for patients younger than 5 years, which may reflect challenges in classifying sudden, severe asthma in this population as well as in administering appropriate therapy and, to some extent, the differences in various guidelines available. Table 1 presents the recommendations for starting corticosteroid treatment, including doses, for children with acute asthma found in selected, commonly used guidelines and practice parameters. Although each recommends initial treatment with a short-acting bronchodilator (preferably inhaled) and oxygen as needed to maintain a saturation level Ͼ90% to 94%, no 2 are alike in their corticosteroid recommendations for children.
METHODS
A comprehensive review of the literature was performed on the topic of using oral corticosteroids (OCSs) to treat acute asthma in children. The literature included full-length papers in English published in peer-reviewed medical journals and non-English articles published with English abstracts. The articles were selected on the basis of a broad literature search using the Medline database (January 1966 -October 2002) and the Embase database (January 1980 -August 2002 . Key text words included but were not limited to pediatric asthma, childhood asthma, acute asthma, and corticosteroid. Articles obtained were further searched for relevant references published before 1966.
SUDDEN SEVERE ASTHMA IN YOUNG CHILDREN
According to national guidelines, an asthma exacerbation can be defined as an increase in symptoms with a decrease in pulmonary function as measured by spirometry or peak flow and/or increased use of bronchodilators. 10 For children, the American Academy of Pediatrics has defined an asthma exacerbation as "an abrupt and/or progressive worsening of symptoms of shortness of breath, wheezing, chest tightness, or some combination of these . . . [with] associated respiratory distress with documented and quantified decreases in expiratory airflow when measurements of lung function are obtained." 13 Obtaining measurements of lung function is the critical diagnostic factor differentiating evaluation of the very young patient with acute asthma. Most asthma patients-including school-age childrencan sense significant airflow limitation even when symptoms seem minimal; the airflow obstruction can be documented by either spirometry or peak flow measurements. 19 For this reason, the patient's assessment of his or her symptoms is critical to evaluating exacerbation severity. However, for infants and young children who cannot communicate a feeling of airflow limitation, exacerbations may have a rapid and unexpected onset and additional deterioration may occur quickly. 4, 19 Immediate attention is needed and should include the child's degree of alertness and responsiveness to the environment, the child's color, and the observed level of respiratory distress. For infants, the ability to feed or suckle and the quality of crying also are important. 4, 13, 19 Exacerbations can be classified as mild, moderate, or severe according to the physiologic and clinical observations described in Table 2 .
Objective measures of lung function during an exacerbation are desired but not usually practical in young children. Children who are aged 5 years and older and regularly use a peak flow meter at home may be able to perform the maneuver in the ED. However, it is unrealistic to expect objective measurements in younger children, children with little experience with peak flow meters, or children in significant respiratory distress. Furthermore, even for children who can use a peak flow meter, the measurement may underestimate the degree of obstruction. 20 For these reasons, a validated asthma severity measure such as the Pulmonary Score described by Smith and Strunk 20 (Table 3 ) may be preferred for young children. This measure uses a scoring scale from 0 (very mild exacerbation) to 9 (very severe exacerbation) and has been tested in children who present to the ED with mild to severe acute asthma and shown to correlate well with the peak expiratory flow rate (PEFR). 20 Rapid identification and classification of respiratory distress can significantly enhance treatment outcomes and reduce complications. However, a pattern of recurring exacerbations or severe symptoms treated in the ED can signal a child with particular risk factors for morbidity. 4, 10 Thus, once the initial assessment is made and treatment is initiated, the clinician should address the child's history. For the current exacerbation, significant factors include the duration of symptoms, symptom triggers, recent upper respiratory infections (URIs), vomiting, use of rescue medications (including time of last dose), and use of long-term controller medications. Information should also be obtained regarding previous exacerbations including the number of courses of OCSs, ED visits, and hospitalizations for asthma in the past year; the last ED visit and/or hospital admission; the last course of OCS; and any intensive care unit admissions or intubations. 4, 10, 20 Past ED visits and hospitalizations are red flags indicating children whose asthma is poorly controlled, regardless of age. 10 These patients' symptoms may be unstable and can deteriorate rapidly and unexpectedly. In addition, the older child whose history includes rapid onset (ie, Ͻ3 hours) of severe symptoms is at increased risk for sudden deterioration and should be watched carefully and treated aggressively. 20 
TREATING ACUTE ASTHMA IN CHILDREN
Asthma exacerbations in children should be treated promptly and aggressively at home (Fig 1) and/or in the ED, depending on symptom severity (Fig 2) . The first line of treatment for exacerbations of wheeze at home is adequate dosing with a shortacting ␤ 2 -agonist, preferably administered by inhalation. As shown in Fig 1, follow-up is determined by the initial response to bronchodilator therapy. 4, 10 In each case, the child's physician should be notified. If the exacerbation is mild and there is a good response to bronchodilator (ie, PEF returns to normal in a capable child), then nothing more is needed other than observation and continued ␤-agonist treatment as shown in Fig 1. If the child is using an inhaled corticosteroid (ICS), then a step-up in dose should be considered. 4, 10 For any other outcome, an OCS is added to the initial bronchodilator therapy; the child with a severe exacerbation or poor response to treatment (ie, continued marked wheezing or shortness of breath; PEF Ͻ50% predicted in a capable child) needs to be assessed in the ED. 4, 10 Most children who are seen in an ED for an acute episode of wheezing receive systemic corticosteroids as recommended by national and international guidelines. 4,6 -14 The current approach to treatment in the United States is shown in Fig 2. However, despite adoption of the national guidelines, significant variation exists in how older and younger children are treated for asthma exacerbations in the ED: older children are more likely to receive corticoste- 
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The schema is based on the initial assessment of the child in distress and should be used according to the characteristics and needs of the individual child. 12 Pco 2 indicates partial pressure of carbon dioxide. roids. A cross-sectional ED study of viral-induced exacerbations of wheeze reported administration of systemic corticosteroids to 71% of children older than 2 years but only to 45% of children younger than 24 months. 21 The efficacy of systemic corticosteroids to treat exacerbations of asthma in older children and adults is well documented; these agents have been used to treat acute asthma for Ͼ50 years. 20, [22] [23] [24] [25] [26] [27] In most cases, clinical improvement has been reported within several hours, and the available data for children support findings in older patients-that is, early treatment with systemic corticosteroids can reduce both the duration and the severity of an acute episode of asthma. 20, 22, 27 Storr et al 28 showed that for 140 children who were older than 2 years and presented with acute asthma in the ED, a single dose of prednisolone (30 mg in children 2-5 years, 60 mg for children 5 years and older) significantly improved clinical outcomes. Twenty children who received prednisolone were discharged within a few hours compared with 2 children in the placebo group (P Ͻ .0001). For children who remained in the hospital, the mean duration of stay was 24 hours for the prednisolone group and 39 hours for the children who received placebo (P ϭ .0011). In addition, for the hospitalized children, early administration of the corticosteroid was associated with a reduced need for added corticosteroids: 20 children in the prednisolone group and 44 children in the placebo group required more corticosteroids during their hospital stay (P ϭ .0005). 28 Similar results were reported in a double-blind, placebo-controlled trial by Scarfone et al, 29 who showed that 1 dose of oral prednisone (2 mg/kg) administered on admission to the ED significantly decreased the pulmonary index over a 4-hour period (P Ͻ .001) in 75 children between the ages of 1 and 17 years. The subsequent hospitalization rates were 31% (11 of 36) for children who were treated with the corticosteroid compared with 49% (19 of 39) for placebo-treated children. The between-treatment difference for hospital admissions increased with ex- acerbation severity: for children who presented with an initial pulmonary index Ͼ10, the hospitalization rates were 32% and 72% (P Ͻ .05) in the prednisone and placebo groups, respectively. 29 Other studies suggest that continued administration of oral (or inhaled) corticosteroid for 3 to 7 days after the initial exacerbation may provide added benefit. 30 -33 Table 4 presents the significant findings of con- trolled clinical trials of OCSs for acute exacerbations of asthma in children, compared with placebo or with other formulations of corticosteroids. These can be summarized as follows:
1. OCSs are effective for the outpatient treatment of acute asthma. OCSs were more effective than placebo in the outpatient treatment of acute asthma (ie, when administered at home, in the doctor's office or clinic, or in the ED). Of the 17 outpatient studies included in Table 4 , only 2 reported lack of efficacy with corticosteroid treatment. 34, 35 Both studies involved treatment given at home or in the clinic (ie, milder episodes for which the child was not taken to an ED). Another study reported equivocal results in 28 children who were treated with tapering doses of methylprednisolone or matching placebo over the course of 1 week. 36 These children had presented to the clinic with acute exacerbations requiring at least 3 consecutive treatments with bronchodilator and were well enough to go home but still had measurements of forced expiratory volume in 1 second below 80% of their personal baseline. Trends favored the corticosteroid, but statistical significance was not attained. Reviewing the data, the investigators suggested that the between-treatment differences would have been more dramatic with increased exacerbation severity. 36 Review of Table 4 supports this: significant between-treatment differences favoring corticosteroid therapy are more likely to be reported for studies of children who present to an ED for their acute asthma. 28, 30, 37 For the majority of the outpatient clinical trials, early treatment was associated with shortened duration of the exacerbation, reduced severity of acute symptoms, and fewer complications-including hospital admissions and relapses requiring additional treatment-after the exacerbation. 28 4 . The critical factor for a positive outcome is early administration of the corticosteroid. The most important factor for a positive clinical response to treatment of acute asthma with corticosteroids was early administration at the first sign of symptoms if given at home or within 1 hour of presentation if administered in the ED. For children who had to be hospitalized for their exacerbation, early and continued administration of a corticosteroid was associated with a shorter duration of hospital stay, quicker improvements in arterial oxygen pressure and pulmonary index scores, and fewer relapses after discharge. 28, 29, 32, 41, 42, 46, 47 In children with "milder" exacerbations that were not seen at the ED, administration of the corticosteroid on first symptoms was associated with fewer relapses requiring subsequent rescue interventions and/or ED visits or hospitalizations. 30 Table 4 compared different formulations of corticosteroids in the treatment of children with acute asthma seen in the ED. 32, 33, [41] [42] [43] [44] [45] All routes of delivery were effective, but there are drawbacks to using IV or inhaled routes of delivery. The former may be preferred for the hospitalized child, although comparisons in this population have shown at least comparable results for IV and oral administration of corticosteroids. 45, 46, 48 In the outpatient setting, IV delivery is not preferred because of its potential for complications and difficult set-up (particularly in young children). 27 Intravenous therapy is also more costly than oral treatment. Although studies have not compared costs in the outpatient setting, a study in children who were hospitalized for acute asthma reported substantial savings when an OCS was substituted for IV dosing. 47 It is difficult to draw conclusions from the available outpatient comparisons of oral and ICSs for acute asthma because of the variability in study methods and outcome measures used. In the studies included in Table 4 , inhaled therapy was associated with a range of outcomes, which may be attributed to differences in route of administration (eg, face mask vs mouthpiece) and the child's ability to inhale medication effectively. Six of the 7 studies compared inhaled and oral formulations. Three showed no significant differences in outcomes when using an OCS or an ICS in the ED treatment of acute asthma. 33, 43, 44 One study suggested some advantages with highdose inhaled budesonide compared with oral prednisolone, 42 and another indicated better outcomes with nebulized dexamethasone compared with prednisone. 31 Schuh et al 32 reported oral prednisone to be better than inhaled fluticasone propionate in reducing the signs and symptoms of an acute exacerbation of asthma evaluated at 4 hours posttreatment. The use of different inhaled medications, different means of delivery, and different doses and frequency of dosing makes generalizations about efficacy problematic. There is no effective way to determine how much inhaled medication reached the airways in these studies or how much had relevant systemic effects. 49, 50 A meta-analysis of the efficacy of ICSs to treat acute asthma presenting in the ED in older children and adults reported a lack of evidence to support use of these medications alone (ie, without addition of systemic corticosteroids). 51 As for intravenous treatment, ICSs have higher acquisition costs than oral formulations. Thus, OCSs remain the preferred treatment for most children with acute asthma in the outpatient setting.
The limited use of OCSs for asthma exacerbations in young children contrasts with the 50ϩ-year history of positive outcomes in adults and older children. This probably reflects both fears of side effects and inconsistencies in reported clinical data between children and adults. Controlled studies of therapy for acute asthma are limited in children younger than 5 years, and this population would not be expected to provide objective lung function data because of difficulties in maximizing ventilatory efforts and difficulties in detecting small changes in function in children's airways. 10, 14, 26 However, clinical benefits have been observed for some infants and toddlers with the corticosteroid administered either at home at the first sign of an exacerbation or in the hospital (Table 4) . 38 -40 For young children who present with acute, severe wheezing in the ED, a controlled trial showed that corticosteroid treatment within 30 minutes of arriving at the ED was associated with a significant improvement in pulmonary index scores (P Ͻ .01) at 3 hours and lower hospitalization rates in children younger than 24 months. 52 In this case, methylprednisolone was administered intramuscularly (4 mg/kg). The hospitalization rates were 18% for the infants and toddlers who received the corticosteroid and 50% for those who were treated with placebo (P Ͻ .05). 52 The effect of single doses or short-term courses of systemic corticosteroids on acute asthma is 2-fold: 1) interfering with the inflammatory cascade underlying the asthmatic response and 2) enhancing the responsiveness of the ␤ 2 receptor in the bronchial smooth muscle. 10, 23, 53, 54 The latter probably accounts for the rapid (ie, within hours) efficacy of corticosteroids for asthma exacerbations, particularly in patients with incomplete responses to bronchodilator therapy-children as well as adults. 4, 10, 23, 37, 39, 44 
CONSIDERATIONS FOR CHILDREN WITH RECURRENT VIRUS-INDUCED EXACERBATIONS
OF ASTHMA Viral respiratory infections are associated with wheezing illnesses and asthma exacerbations in children and adults and are estimated to account for up to 85% of acute childhood asthma episodes. It is not uncommon for children who present with an "asthma attack" to have a history of a URI just before symptom onset. 30,55-58 A 12-month prospective study looked at the relationship between symptomatic URIs and asthma in 20 school-aged children (7-13 years) and 37 older subjects (14 -55 years). 56 URI symptoms, asthma symptoms, medications, and peak flow rates were recorded twice daily on diary cards. A total of 139 symptomatic URIs were reported; 44% (61) immediately preceded (within 24 hours) or coincided with the onset of an asthma exacerbation, and 47% of all asthma exacerbations were associated with viral symptoms. Compared with acute asthma episodes not associated with URIs, the viral-associated exacerbations had significantly greater asthma symptom and severity scores (P Ͻ .05, P Ͻ .001, respectively; Fig 3) . URIs also were associated with trends toward lower peak flow rates and use of more asthma controller medication. 56 An earlier community-based, longitudinal study of 108 school-aged children (9 -11 years) reported a substantially higher association between viral respiratory infections and acute asthma episodes. 58 This study looked at 292 asthma exacerbations over 13 months and included viral analyses using reverse transcription-polymerase chain reaction. In this school-age population, URIs were associated with 80% to 85% of the exacerbations. Picornaviruses (predominantly rhinovirus) were the most common infective agents. 58 Similar observations have been made for very young children for whom the occurrence of asthmalike symptoms (eg, wheezing, nocturnal cough, difficulty breathing) is more frequently reported with viral respiratory infection than with environmental exposures. 4, 10 In fact, viral respiratory infections are the most common cause of asthma exacerbations among children younger than 5 years-the population with the highest ED visit and hospitalization rates for asthma. 4, 10 In reviewing the data on viral-induced asthma exacerbations in school-aged children and toddlers, 3 points of differentiation are evident. First, most toddlers with asthma have symptoms only during the viral season and not year round. 57, 58 Second, unlike older children, few toddlers show positive skin tests to aeroallergens. Third, respiratory syncytial virus (RSV), not rhinovirus, predominates as the infectious trigger. 21,56 -59 Similar to the study in school children reported by Johnston et al, 21 a cross-sectional ED study of 22 wheezing infants (0 -24 months), 48 wheezing children (2-16 years), and 59 matched control subjects reported an association between asthma exacerbations and respiratory viral infection in 82%   Fig 3. Increased severity of acute asthma symptoms in relation to URIs in 20 school-aged children (7-13 years) and 37 older subjects (14 -55 years) over 12 months. 56 Compared with acute asthma episodes not associated with URIs, the viral-associated exacerbations were associated with significant increases in the expression of asthma symptoms (left bars) and overall asthma severity scores (right bars); not shown, URIs were also associated with lower peak flow rates and increased use of asthma medication. 56 to 83% of all children with wheeze. Viral analysis of nasal washes by reverse transcription-polymerase chain reaction demonstrated positive antigen for RSV in 68% of the wheezing infants (Յ24 months) and for rhinovirus in 71% of the children older than 2 years. Also, although nasal eosinophilia, serum eosinophil cationic protein levels, and total immunoglobulin E-characteristics of allergic inflammation-were not correlated with wheezing in the infants, all were significantly associated with asthma exacerbations in the 2-to 16-year group and were substantially higher in older children who were rhinovirus positive. 21 In North America, RSV and influenza virus infections usually peak in early winter to early spring; the peak season for rhinovirus infections is early autumn. Asthma exacerbations related to symptomatic URIs are more likely to occur at these times (ie, the "cold season"), and a temporal relationship has been determined for pediatric ED visits for wheeze and peak viral activities. 21, 57 The clinical implications of asthma exacerbations caused by viral infection relate to the sudden onset of severe symptoms, increased airway responsiveness, and the potential for future asthma. 4,59 -62 It is not unusual for asthma symptoms to occur suddenly and unexpectedly for children with respiratory infections, even normally asymptomatic children with very mild asthma. 4, 21, 57 In the community-based study reported by Johnston et al, 56 most of the children had stable baseline PEFR (median: 312 L/min) but experienced a sudden severe fall (median maximal fall: Ͼ81 L/min) with viral infection. PEFRs returned to baseline levels during a 7-to 24-day period. However, although PEFRs may return toward baseline, increased airway responsiveness as a result of respiratory infections can linger, resulting in heightened sensitivity to environmental factors (eg, temperature, humidity, allergens, pollutants) for extended periods of time. 57 Results of the Tucson Children's Respiratory Study and the Melbourne Asthma Study suggest that respiratory infections very early in life, particularly those caused by RSV, may have a negative impact on lung function for years after the initial episode. 63, 64 RSV-induced bronchiolitis severe enough to cause hospitalization in infants and toddlers has been associated with a significantly increased risk for developing asthma in the preschool and early school years (by age 7.5 years); the risk ratio for future asthma was greater than a family history of atopy or asthma. 62 The argument for early administration of corticosteroid to the child with recurrent viral-related exacerbations of asthma thus reflects the potential for increased severity of airway obstruction later in life, as well as the potential for sudden severe loss of airway function despite minimal disease. Table 5 shows the US recommendations for treating children who have acute asthma with recurrent URIs. 4 Despite these recommendations, children with established patterns of recurrent asthma episodes with viral infections are frequently undertreated. Review of the data on corticosteroids for acute, pediatric asthma suggest that giving an OCS at home could prevent some ED visits for acute asthma. 30,38 -40 However, this remains the exception rather than the rule, and often the young patient with viral episodes of acute asthma is started on long-term inhaled therapy. Although ICSs are the recommended treatment for persistent asthma, data on continuous treatment with ICS for virus-induced wheezing in preschool children is equivocal. 4, 10, [65] [66] [67] [68] Data for older children with predominantly intermittent asthma and several viral-induced exacerbations of symptoms per year are more difficult to interpret, being dependent on the investigators' definitions of persistent and intermittent asthma. 55, [67] [68] [69] However, on the basis of a review of the acute asthma literature, it is likely that early administration of an OCS might help prevent virus-induced severe exacerbations of asthma in children who are susceptible to these episodes.
Brunette et al 38 reported the results of a 2-year study showing that preschool children who experienced repeated asthma episodes associated with viral infections benefited from early administration of short courses of OCSs. During the first year, all of the children received bronchodilators on a continuous basis or intermittently for acute attacks, according to the child's symptoms. For severe exacerbations, albuterol was also given by nebulization and corticosteroids were occasionally added (up to 14 days). During the second year, the children were randomized to 2 groups: one that continued on the previous year's treatment protocol and another that was given a short course of prednisone (1 mg/kg) at the first sign of an URI and before any sign of wheezing. Compared with year 1, children who were treated with OCS in year 2 had significant decreases in the numbers of wheezing days (65%; P Ͻ .001), exacerbations (56%; P Ͻ .002), ED visits (61%; P Ͻ .001), and hospitalizations (90%; P Ͻ .001). The investigators concluded that preschool children who experience repeated asthma attacks related to URIs might benefit from preventive administration of OCSs. 38 
DEVELOPING A PROTOCOL BASED ON EFFICACY AND SAFETY
The advantage of early use of OCSs relates to the importance of timing when treating an asthma exacerbation. Efficacy is best with early treatment; for children with viral-induced wheezing, data and clinical experience suggest that prevention is conceivable only when treatment can be given at the first sign of upper respiratory symptoms (ie, at home). 38 Although more clinical data are needed, it is likely that administration of a short course of OCSs (3 to 5 days) early during a viral infection will decrease the number of young children who are seen at the ED as well as related hospital admissions. Whether early use of OCSs in children with mild asthma and viral-induced exacerbations can slow the development and/or progression of disease severity over time remains a topic for study. Related to this are the questions of how long and how often therapy can be given safely. The choice of medication for infants and toddlers, in particular, requires careful assessment, balancing efficacy and safety as well as the child's ability to tolerate the delivery system and to comply with dosing. 4 Although oral administration may be the optimal means of treating very young children with asthma, existing observations suggest that the oral route may be preferable for acute exacerbations in older children as well. The real questions are how much and how often medication can safely be given, balancing the known risks associated with OCS use. There is no doubt that daily administration for extended periods, such as is used for treating severe, persistent asthma, is associated with adverse events. However, to date, short-term, limited use of OCSs-even several times per yearhas not been associated with significant side effects in most children. 28 -45 Controlled data on the safety of short courses of OCSs to treat children with acute asthma are limited and largely anecdotal, and data on the adverse events associated with pediatric corticosteroid use in other diseases has largely been reported ad hoc. Regular treatment with OCSs for periods of 2 to 6 months has been reported to reduce morbidity and mortality in children with nephrotic syndrome; compared with 2 months of treatment, 3 months or more is associated with fewer relapses, while not increasing adverse events. 70, 71 Short courses of OCSs to treat exacerbations for asthma last for days, not months. When used infrequently, this therapy has no serious systemic side effects in most children; however, frequent short courses increase the potential risk of adrenal suppression, depression of linear growth, and osteoporosis. 4, 10 The issue is the definition of "frequent." Empirically, there are no statistics showing that doses of 1 to 2 mg/kg/d (to a maximum daily dose of 4 -50 mg) for up to 30 to 40 d/y have any long-term adverse effects in children. 4, 10, 14, 72 However, some children may be more sensitive to the systemic side effects of corticosteroids, and growth should be followed regularly by stadiometry in all children with asthma. 4, 10, 72 If growth abnormality occurs, then it is important to assess carefully the severity of the disease and the dose and frequency of the corticosteroid treatment. For predominantly asymptomatic children who have several acute, severe asthma episodes yearly, this may be an indicator to start long-term controller therapy. 4, 10 It is well documented that regular treatment of persistent asthma with low to moderate doses of ICSs can reduce ED visits and hospital admissions in children and adults. [72] [73] [74] A study of 86 children (2-16 years) who were treated for an acute exacerbation of asthma reported some behavioral changes associated with use of a higher dose of OCS. 75 These children had moderate, persistent asthma and were using daily ICSs. They were given a 5-day course of oral prednisone (1 or 2 mg/kg/d) after an incomplete response to bronchodilator and ICS treatment of an acute asthma episode. Both doses resolved the acute symptoms; however, more aggressive behavior (P ϭ .002) and anxiety (P ϭ .02) were reported by parents of children using the 2 mg/kg/d dose. 75 
CONCLUSIONS
Review of the literature, including current guidelines for managing asthma, suggests that early treatment of acute asthma symptoms with OCSs in children with a pattern of recurrent acute asthma may decrease the severity of acute asthma episodes, reduce the risk of subsequent relapses, and thereby improve the quality of life for these children and their families. Attention should be given to identifying these children and standardizing a treatment approach based on accepted, consistent definitions of what constitutes an asthma exacerbation and recurrence. The following are suggested as a starting point for discussion:
1. Definition of an asthma exacerbation: an abrupt and/or progressive worsening of asthma symptoms with associated respiratory distress documented by reduction in PEFR (in capable children) of at least 20% and/or an increased need for short-acting bronchodilator. 2. Definition of recurrent asthma exacerbations: Ͼ2 acute asthma episodes during the previous 12 months. 3 . A suggested 3-step treatment plan for children with recurrent asthma exacerbations: The following 3 steps are recommended to be taken by the parent or caregiver at the first sign of an exacerbation (as defined above) or at the first symptoms of a URI in children with recurrent URI-induced acute asthma (even before wheezing is evident): 1) initiate or increase dose of short-acting bronchodilator as directed in asthma management plan; 2) unless contraindicated, start OCS, 1 to 2 mg/kg/d (maximum: 60 mg/d) in 2 to 3 divided doses per day; 3) call the physician.
These recommendations are based on review of the literature and current guidelines for managing asthma as reported here. Validation is required, preferably through controlled and prospective studies designed to address the following questions:
1. What are the appropriate indicators to document outcomes accurately for a) the child with relatively mild acute episodes of asthma usually treated at home, b) the child with more severe acute asthma seen in the ED, and c) the child with recurrent episodes of acute asthma related to respiratory infections? The studies included in Table  4 indicate that at the mild end of the spectrum, results can be difficult to interpret; for these patients, in particular, careful consideration needs to be given to the specific outcome measures as well as to study power for statistical analyses. Also, because pulmonary function tests may not be the best measure for assessing outcomes (and are not appropriate for studies of young children), which objective parameters should be used (eg, relapses over a period of time, ED visits posttreatment)? 2. How long should treatment be given? The studies in Table 4 present a range of treatment options, with similar positive outcomes in many cases: from a single dose of OCS at the start of an acute asthma episode to 7 days of OCS to mixed treatment with oral and ICSs. To minimize side effects, all corticosteroids should be used at the lowest dose possible, and OCSs should be used in short bursts. However, the definition of "short" remains a topic for discussion that must be included in developing a protocol for using OCSs to manage recurrent, acute asthma in children. 3. What dose should be used to treat recurrent acute asthma episodes in children? The recommendations of commonly used guidelines range from 0.5 mg/kg/d to 2 mg/kg/d, and the studies included in Table 4 all fall within this range. 4, 7, 10, 12 Although it is agreed that corticosteroids should always be used at the lowest dose possible, defining an "appropriate lowest dose" to treat the child with acute asthma remains an open question. Between-study comparisons from Table 4 and data from other investigators suggest that doses of 1.0 mg/kg/d and 2.0 mg/kg/d provide similar clinical benefits for most children. 1,28 -45,75 If true, then the lower dose would be preferred because of less risk for side effects. A well-controlled, prospective trial is necessary to address this issue.
Asthma exacerbations represent a failure of overall asthma management, and children with recurrent episodes of acute asthma symptoms should be evaluated and treated appropriately for persistent asthma. This is a challenge in preschool children, for whom diagnosing of asthma can be difficult because of other conditions with similar symptoms and the inability to obtain pulmonary function tests. However, the increasing numbers of preschool children who are seen in the ED for acute asthma indicate that asthma treatment overall is unsatisfactory in this group. There is room for improvement in care pathways for pediatric asthma, and early use of OCSs for children with recurrent acute wheezing may be one approach with significant clinical benefits.
